Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fate TherapeuticsFATE +1.98%33 Market Cap is $307.34 Mil as of Aug. 16, 2026. GuruFocus rates FATE with a GF Score™ of 33/100 and a GF Value™ of $0.79 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,423 Biotechnology companies, Fate Therapeutics ranks better than 63.39% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Fate Therapeutics's share price for the quarter that ended in Jun. 2026 was $2.7. Fate Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 116.69 Mil. Therefore, Fate Therapeutics's market cap for the quarter that ended in Jun. 2026 was $315.07 Mil.
Fate Therapeutics's quarterly market cap
increased
from Dec. 2025 ($113.35 Mil) to Mar. 2026 ($139.53 Mil) and
increased
from Mar. 2026 ($139.53 Mil) to Jun. 2026 ($315.07 Mil).
Fate Therapeutics's annual market cap
declined
from Dec. 2023 ($368.86 Mil) to Dec. 2024 ($187.98 Mil) and
declined
from Dec. 2024 ($187.98 Mil) to Dec. 2025 ($113.35 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Fate Therapeutics's Enterprise Value for Today is $229.25 Mil.
Fate Therapeutics (NAS:FATE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Fate Therapeutics Market Cap Related Terms
Fate Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Fate Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fate Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Fate Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (FATE) has a Market Cap of $307.34 Mil as of Aug. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Fate Therapeutics and its competitors. According to the industry distribution chart, Fate Therapeutics ranks #521 out of 1423 companies in the Biotechnology industry, placing it in the top 36.6%.
Is Fate Therapeutics' Market Cap too high?
Fate Therapeutics' current Market Cap is $307.34 Mil. The Biotechnology industry median Market Cap is 118.89. Fate Therapeutics' value of $307.34 Mil is 158.5% above this industry median. Based on the distribution chart, Fate Therapeutics ranks #521 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Market Cap compare to IMRX and NWBO?
According to the Biotechnology industry distribution chart, Fate Therapeutics ranks #521 out of 1423 companies for Market Cap. This puts Fate Therapeutics in the upper half of its industry. The industry median Market Cap is 118.89. Fate Therapeutics' value of $307.34 Mil is 158.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.89, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fate Therapeutics's current Market Cap of $307.34 Mil is 158.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Fate Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 118.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fate Therapeutics's current Market Cap is $307.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FATE) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.79, compared to a current price of $2.57 — trading 224.7% above its estimated fair value. The current Market Cap is $307.34 Mil and 158.5% above the Biotechnology industry median of 118.89. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Fate Therapeutics (FATE), the current Market Cap is $307.34 Mil as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fate Therapeutics (FATE) Overvalued in 2026?
Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued.
The current stock price of $2.57 is trading 224.7% above its estimated GF Value™ of $0.79.
GuruFocus considers Fate Therapeutics to be Significantly Overvalued.
Key valuation signals for FATE:
Market Cap: $307.34 Mil
GF Value™: $0.79 vs. price of $2.57 (224.7% above fair value)
Industry Position: 158.5% above the Biotechnology median (#521 of 1423)
No single metric tells the full story. See the FATE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score
Get the complete analysis for FATE
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FATE has been successfully added to your 
